Links
Organizations
Conferences
Info & Opinion
October 10, 2008
Litigation Into Perpetuity?
Drug Safety: A Lawyer’s View
A lawyer says litigation illuminates how the pharmaceutical industry thinks and conducts itself. A few forward-looking statements.
Trasylol, Bayer & Three Mile Island
Drug Safety Story Time
Reflections on the power of narrative and the industry’s wobbly reputation.
Three Ticking Clocks
Bayer Halts Trasylol Sales
With journal editors in charge of drug safety, the political system has failed the industry and the public.
The Case For Outreach
Stopping Drug Safety Spin Cycle
Why the pharmaceutical industry’s ill-advised reliance on lobbyists will hamper its efforts to rehabilitate its reputation.
- Home
- Tag
- avandia
When will the drug safety wars end? How will they end? A new president? A Supreme Court decision? We thought Tom Lamb might know. He’s an attorney based in Wilmington, North Carolina. Like it or not, lawyers like Lamb are…
With the Oscars upon us, it’s time to reflect on something simple. Our brains store information and make sense of the world in stories. This is true in all cultures, all individuals. “She saved my career.” “They worked it out.”…
In another significant win for medical journal editors in their new role as regulators, Bayer suspended sales of anti-clotting drug Trasylol (aprotinin), which had been implicated in kidney failure, cardiovascular problems and mortality risk. The drug had approximately $135 million…
A few years ago, thinking the way all journalists think, we had an epiphany. The reportorial brain is the one we’re happily stuck with. But it often adopts a harshly negative, critical outlook that transcends age, geography and political affiliation.…
Concerns about diabetes blockbuster Avandia have been addressed by the mass media, by FDA statements—and by the August 30, 2007, New England Journal of Medicine (NEJM). It’s not a surprise that the journal would have a negative view of the…
GlaxoSmithKline took a bullet from the anti-industry New England Journal of Medicine, which did a meta-analysis of data about the GSK diabetes drug Avandia. The Cleveland Clinic’s Steve Nissen calculates Avandia to raise the odds of cardiovascular-related death by 64…
